Federal appellate judges suggested Monday (Jan. 13) that CMS’ attempt to require that drug makers include list prices in television advertisements might lead to consumer confusion without bringing down drug prices. All three members of an appeals court panel voiced skepticism about the validity of the agency’s price-disclosure rule, which is one of the most prominent elements of the Trump administration’s drug-pricing agenda. CMS issued the rule last May, but a federal district judge blocked it from taking effect because...